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Effect of synthetic human atrial natriuretic peptide (102-126) in
nephrotic syndrome
ROBERT ZIETSE and MAARTEN A. SCHALEKAMP
Department of Internal Medicine I, University Hospital Djkzigt, Erasmus University, Rotterdam, The Netherlands
Effect of synthetic human atrial natriuretic peptide (102.126) in ne-
phrotic syndrome. Synthetic human ANP (102-126) or vehicle was
intravenously administered to eight patients with non-edematous ne-
phrotic syndrome to study its effect on protein and sodium excretion.
ANP was given in ascending doses, each dose for one hour, two to three
days apart. Four patients received 0.03, 0.10 and 0.45 g/kg/min of
ANP, and four received 0.015, 0.06 and 0.20 tg/kg/min. Natriuresis
increased at all doses; by 179 13.6% (mean sEM;P <0.05) at 0.015
jsglkglmin and by 660 71.5% (P < 0.01) at 0.20 tg/kg/min. Urinary
albumin excretion increased by 138 30.1% (P < 0.05) at 0.015
j.tglkg/min of ANP and by 534 132% (P < 0.01) at 0.20 g/kgImin.
Immunoglobulin G excretion increased proportionally to albumin ex-
cretion. Hematocrit and serum albumin concentration increased after
ANP. In each patient the percent reduction of plasma volume calcu-
lated from the effect on serum albumin was smaller than the hemocon-
centration calculated from the effect on hematocrit, suggesting a loss of
albumin from the intravascular compartment. This could not be ac-
counted for by the increased glomerular filtration of albumin. Blood
pressure and effective renal plasma flow decreased and filtration frac-
tion increased after ANP. Plasma renin was suppressed at lower doses
of ANP but was stimulated, together with plasma noradrenaline, at
higher doses. Basal plasma ANP levels were normal and rose at the
lowest dose to levels slightly above the physiological range. Thus, ANP
appears to increase the transcapillary filtration of intravascular protein
in the glomerulus and possibly elsewhere in the body. In non-edema-
tous patients with nephrotic syndrome the proteinuric and natriuric
effects of ANP were already seen at low doses. Endogenous ANP may
therefore have similar effects in these patients.
Mammalian atria contain peptides with potent natriuretic,
diuretic and vasorelaxant properties [1]. A series of these
peptides, derived from a larger precursor molecule, have been
isolated. In humans a single peptide, human atrial natriuretic
peptide (99-126), which consists of the 28 amino acids of the
carboxy-terminal of its precursor molecule, appears to be the
main circulating form [2]. The effects of synthetic ANP prepa-
rations on urinary sodium and water excretion and on systemic
and renal hemodynamics have been studied in healthy volun-
teers and in patients with essential hypertension, congestive
heart failure and liver cirrhosis [3—5].
This paper reports on the effects of incremental doses of
synthetic human ANP (102-126) on urinary excretion of sodium
and water in patients with nephrotic syndrome. Since it is not
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known whether ANP has an effect on urinary protein excretion,
we also report on the changes in urinary albumin and immuno-
globulin G following ANP administration in this particular
group of patients. The tubular capacity of protein reabsorption
is saturated in nephrotic syndrome so that changes in urinary
protein excretion are a measure of changes in filtered protein
[6]. In addition, we measured the effects of ANP on hematocrit,
serum albumin, blood pressure, giomerular filtration rate and
renal plasma flow, as well as on plasma renin and noradrena-
line.
Methods
Study protocol
The study was performed in eight male subjects with ne-
phrotic syndrome (proteinuria 4.0 to 9.0 g/24 hr) who had only
moderate impairment of renal function (Table 1). There was no
evidence of any other than renal disease. Following a two week
run-in period in which all medication was discontinued, 24-hour
urinary sodium excretion was measured on two consecutive
days. Daily sodium intake was then adjusted to the average
24-hour sodium excretion at the end of the run-in period. When
sodium balance was achieved (24-hr urinary sodium excretion
within 15 percent of daily sodium intake), the patient was
admitted to the hospital. Infusions of placebo and three incre-
mental doses of ANP were given, each after a two to three day
interval. Four patients (group A) received human ANP (102-
126) at a rate of 0.03, 0.10 and 0.45 g/kg/min. Because
significant effects on urinary sodium and protein excretion were
already seen at doses as low as 0.03 and 0.10 p.g/kglmin, we
studied a second group of four patients (group B) at a dose rate
of 0.015, 0.06 and 0.20 g/kg/min.
After a light breakfast patients drank tap water, 20 ml/kg
body wt in 20 minutes. Plastic cannulas were then inserted into
an antecubital vein of each arm. One arm was used for infusion
of ANP, thalamate and hippuran, while blood samples were
drawn from the other arm. Glomerular filtration rate (GFR) and
effective renal plasma flow (ERPF) were determined by a
constant infusion technique, by measuring the renal clearances
of '251-thalamate and '311-hippuran (Amersham, UK), respec-
tively. The priming dose was 0.08 to 0.1 tCi/kg for thalamate,
and 0.3 to 0.4 MCi/kg for hippuran. The sustaining infusion rates
were 0.05 and 0.2 tCi/min, respectively [7].
Patients remained in the supine position but were allowed to
stand in order to pass urine. After the water load, urine was
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Table 1. Clinical patient data
collected at 20 minute intervals and blood samples were taken
at the midpoint of each collection period. A steady-state (two
consecutive urine collections varying less then 1 mI/mm) was
achieved after approximately 120 minutes. The average of the
two last urine collections served as baseline. After each urine
collection the urine volume was measured, and that volume
plus I mi/mm (insensible loss) was replaced orally. Following
the baseline period, human ANP (102-126) (Wy 47.663, Wyeth
Research Laboratories, Philadelphia, Pennsylvania, USA) in
vehicle (0.005 M acetic acid in 5% glucose containing 100 mg/mI
Basal Basal
urinary urinary
Body protein Serum sodium
Patient Age weight excretion creatinine excretion
group Diagnosis yr kg g/24 hr p.mol/liter mmol/24 hr
A Membranous glomemlonephritis 36 91.5 4.0 86 123
A Alport's syndrome 25 80.5 4.5 301 192
A Hereditary glomerulonephritis 22 58,5 8.0 148 136
A Membranous glomerulonephritis 19 70.5 8.0 94 170
B Focal segmental glomerulosclerosis 35 69.3 6.0 105 70
B Membranoproliferative glomerulonephritis 55 71.5 7.5 202 135
B Minimal change disease 45 67.7 7.5 83 125
B Alport's syndrome 22 70.5 9.0 116 176
Table 2. Effects of human ANP (102-126)
Mean
Plasma blood Serum Plasma Plasma
ANP pressure Heart rate Hematocrit albumin renin noradrenalin,
Dose pmol/liter mm Hg bpm liter/liter gluier iU/ml pmol/mI
Group A
Vehicle
0 mm 18.9 1.3 105 3,3 67.1 3.8 0.46 0.02 29,4 1.5 20.2 3.0 1.50 0.18
60 mm 17.8 1.5 101 3.4 64.6 3.5 0.45 0.02 29.6 1.6 19.7 2.5 1.54 0,11
180 mm 102 3.2 63.9 4.1 0.46 0.02 29.1 1.5 18.9 3.3 1.59 0.08
ANP 0.03 pg/kg/min
0 mm 16.3 3.1 98.0 6.2 64.3 4,0 0.45 0.01 28.9 1.9 31.8 6.9 1.48 0.14
60 mm 154 14" 89.5 6.4a 65.4 4.0 0.47 0.01 29.0 2.1 17.7 3.8a 1.89 0.13
180 mm 91.8 5.0 61.6 3.5 0.45 0.01 28.3 2.3 31.9 3.7 1.56 0.11
ANP 0.10 sg/kg/min
0 mm 18.8 3.6 98.2 4.6 65.3 3.2 0.43 0.01 29.0 1.5 47.8 7.5 1.69 0.17
60 mm 721 100b 80.6 3.8" 68.7 4.9 0.46 0.OIa 31.5 2.3a 43.1 8.4 2.22 0.13"
180 mm 88.5 5.1k 64.6 2.1 0.43 0.01 27.3 1.6 43.0 6.9 1.60 0.04
ANP 0.45 p.g/kg/min
0 mm 19.8 3.9 98.8 4.7 60.5 4.6 0.40 0.01 29.2 1.3 38.1 7.4 1.57 0.11
60 mm 2170 410b 80.5 50b 737 7.2a 0.44 0.Ola 32.8 2,2a 96.6 95 3.22 0.10"
180 mm 87.5 3.Oa 68.1 7.3 0.41 0.01 28.0 1.8 47.7 6.7 1.95 0.11
Group B
Vehicle
0 mm 21.3 1.0 102 3.1 69.1 3.7 0.38 0.02 29.2 1.3 17.9 3.1 1.64 0.19
60 mm 20.0 1.4 101 3.0 64.6 3.5 0.38 0.02 29.6 1.6 18.2 2.5 1.59 0.11
180 mm 100 3.4 64.6 4.1 0.38 0.02 29.5 1.4 18.1 3.3 1.70 0.10
ANP 0.015 g/kg/min
0 mm 14.3 2.7 104 2.4 69.1 6.7 0.37 0.02 31.2 1.7 34.6 7.8 1.79 0.23
60 mm 103 16" 98.5 2.7 69.5 5.4 0.38 0.03 32.0 1.6 25.4 5.6 2.08 0.19
180 mm 99.9 2,2 65.9 6.5 0.37 0.02 30.0 1.6 23.7 3.4 2.04 0.16
ANP 0.06 pg/kg/min
0 mm 19.3 4.3 103 5.5 66.2 5.7 0.34 0.02 30.9 1.3 26.8 1.6 1,57 0.07
60 mm 381 71" 91.6 4,1 68.8 6.7 0.36 0.02 32.3 1.3 34.9 5.4 1.75 0.16
180 mm 101 4.5 65.1 4.9 0.34 0.02 29.8 1.0 32.9 5.2 1.59 0.08
ANP 0.20 ag/kg/min
0 mm 19.5 3.3 99.4 3.5 69.8 4,2 0.30 0.02 31,5 0.2 26.3 3.5 1.17 0.07
60 mm 939 80 90.2 1,4k 70.8 5,8 0.35 0.03 33.5 0.6 31.9 5.0 1.73 0.l2a
180 mm 95.8 2.3 65.3 4.6 0.31 0.02 31.3 0.4 27.9 2.4 1.36 0.12
Values are means SEM (N = 4).
a P < 0.05 versus time 0 mm
b p < 0.01 versus time 0 mm
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Table 3. Effects of 60 mm infusion of human ANP (102-126)
Dose
Albumin
excretion
mg/mm
Fractional
excretion of
albumin %
GFR ERPF
Filtration
fractionmi/mm
Group A
Vehicle
0 mm 2.2 1.0 0.09 0.02 100 9.7 460 75.3 0.23 0.02
60 mm 2.1 1.8 0.11 0.03 101 11 456 72.9 0.24 0.01
180 mm i.i 0.8 0.07 0.04 100 11 452 69.9 0.24 0.02
ANP 0.03 p.g/kg/mmn
0 mm 2.1 1.0 0.08 0.04 95.4 7.8 466 50.5 0.22 0.02
60 mm 6.8 6.2a 0.30 o.osa 99.6 7.9 406 32.4 0.25 0.0l
180 mm 1.4 3.8 0.06 0.02 108 8.7 508 27.8 0.23 0.01
ANP 0.10 p.g/kg/min
0 mm 1.6 1.2 0.07 0.04 103 6.7 527 48.5 0.22 0.02
60 mm 5.9 3.8a 0.90 006b 107 9.7 441 49•9a 0.25 o.ola
180 mm 1.0 0.8 0.05 0.02 111 10 468 52.1 0.25 0.01
ANP 0.45 ugIkg/min
0 mm 1.7 1.2 0.12 0.03 106 8.4 544 83.0 0.21 0.01
60 mm 12 68b 0.38 0.IOa 104 8.4 415 449a 0.31 002b
180 mm 1.4 1.0 0.06 0.01 110 11 434 52.3 0.26 0.01
Group B
Vehicle
0 mm 4.1 1.6 0.11 0.02 98.9 9.6 445 74.4 0.22 0.01
60 mm 4.4 2.4 0.13 0.03 99.3 10 442 73.7 0.23 0.02
180 mm 2.3 0.8 0.09 0.04 100 12 440 68.1 0.22 0.02
ANP 0.015 /.Lg/kg/min
0 mm 3.7 2.8 0.11 0.04 87.4 7.7 445 68.2 0.22 0.01
60 mm 8.8 2.2a 0.29 o.osa 86.8 8.9 370 47.6 0.24 0.01
180 mm 3.7 2.2 0.13 0.02 85.3 7.9 394 54.6 0.25 0.01
ANP 0.06 p.g/kglmin
0 mm 4.2 2.0 0.14 0.04 95.4 8.8 522 102 0.21 0.02
60 mm 12.0 3.6a 0.35 0.06 93.7 10 403 62.2a 0.25 0.02
180 mm 3.9 0.8 0.13 0.02 89.5 II 423 79.2 0.23 0.01
ANP 0.20 g/kg/mmn
0 mm 3.1 0.6 0.11 0.03 85.5 8.1 456 77.4 0.21 0.02
60 mm 19.7 15l 0.45 o.loa 88.3 9.7 433 74.6 0.23 0.02
180 mm 3.5 1.8 0.1 0.01 83.5 12 421 87.1 0.22 0.02
Values are means SEM (N = 4).
a P < 0.05 versus time 0 mm
b p < 0.01 versus time 0 mm
mannitol) or placebo (vehicle) were infused intravenously for 60
minutes. Following the infusion the collection of urine and
blood samples was continued for 120 minutes. The amount of
sodium excreted above baseline during each experiment (infu-
sion period and the 120 mm thereafter) was replaced in divided
doses by giving sodium chloride capsules, two capsules a day,
on the days between the experiments.
Blood pressure and heart rate were measured at 10 minute
intervals before and after the infusion of ANP or vehicle and at
two minute intervals during the infusions.
Hematocrit and the plasma concentrations of renin and
noradrenaline were measured before and after 60 minutes of
infusion of ANP or vehicle, and at the end of the experiment 120
minutes after the infusion had been stopped. The serum and
urinary concentrations of albumin, sodium, '311-thalamate and
'251-hippuran were measured in each 20-minute clearance peri-
od.
The experimental protocol was approved by the hospital
ethical committee, and informed consent was obtained from the
patients participating in this study.
Analytical methods
Blood pressure was determined with an oscillometric device
(Accutorr, Datascope Corp, Paramus, New Jersey, USA). The
means of three consecutive readings were used for analysis.
Serum albumin concentration was measured by means of the
bromocresol green binding method on the Technicon SMAC
[8]. Urinary albumin and immunoglobulin G (IgG) concentra-
tions were measured by single radial immunodiffusion using the
method described by Ingild [9]. The between-run coefficients of
variation were 1.7% for the bromocresol green method and
5.0% for the radial immunodiffusion.
The plasma concentration of active renin was measured by
radioimmunoassay [10]. Plasma noradrenaline was determined
by high pressure liquid chromatography with electrochemical
detection [11]. Plasma and urinary 125! and 1311 activity were
measured in a gamma scintillation counter.
Plasma ANP levels were measured by Dr J. Nussberger
(Centre Hospitalier Vaudois, Lausanne, Switzerland), after
extraction, by radioimmunoassay using an antibody directed
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SD).
Calculations
PV
—
11(1 — Hct0) — 1
PVo 1/(1 — Hct) — 1
PV
—
A1b0
PV0 A1b
Statistical analysis
Results
ANP were 103 16 pmol/liter (P <0.01) at an infusion rate of
0.015 1.tg/kg/min and 2170 410 pmollliter (P < 0.01) at 0.45
pgIkgImin (Table 2). ANP returned to baseline about 15 minutes
(E 1) after the infusion had been stopped.q. Sodium excretion increased at each dose of ANP (Fig. 2,
Table 4); it increased by 179 13.6% (P < 0.05) at 0.015
j.tg/kg/min of ANP and by 660 71.5% (P < 0.01) at 0.20
pgIkg/min. Urine production also increased significantly at all
doses of ANP, except at the lowest dose in group A (0.03
gg/kglmin).
During ANP infusion urinary albumin excretion increased at
(Eq. 2) each dose (Fig. 3, Table 4); it increased by 138 15.1% (P <
0.05) at 0.015 tg/kg/min of ANP and by 534 66.2% (P < 0.01)
at 0.20 gglkglmin. Changes in IgG excretion were parallel to
those in albumin excretion (Fig. 3, Table 4). IgG excretion
increased by 83.3 16.5% (P < 0.05) at 0.015 j.tg/kg/min of
ANP and by 300 25.1% (P < 0.01) at 0.20 tg/kg/min. The
change in total albumin excretion was proportional to the
change in fractional excretion (albumin clearance/creatinine
clearance, Table 3).
Infusion of ANP had no significant effect on GFR, but ERPF
decreased significantly at infusion rates of 0.06, 0.10, and 0.20
sg/kglmin (Table 3). Filtration fraction (GFRIERPF) increased
by 19.0 6.1% (P < 0.05) at 0.06 p.glkg/min of ANP and by 47.6
12% (P < 0.01) at 0.20 p,glkglmin.
Hematocrit increased at 0.10, 0.20 and 0.45 p,glkglmin of
ANP (Table 2). Serum albumin also increased at these doses of
ANP.
Blood pressure fell during infusion of ANP at all doses (Table
2), except the lowest (0.015 tgIkg/min). At high doses the effect
on blood pressure lasted throughout the 120 minute period
following infusion. Heart rate rose only at the highest dose of
ANP (0.45 tg/kg/min, Table 2).
Plasma renin was suppressed at 0.03 p.g/kg/min of ANP
(Table 2). Renin did not change after infusion of 0.06 to 0.20
Table 4. Increase in urinary flow and sodium and protein excretion
following infusion of human ANP (102-126)
Infusion
Dose
sg/kg/min
Urine
ml
Sodium
mmol
Albumin
mg
IgG
Group A
0.03 105 9.1? 16? 2.7a
0.10 23? 15.3a 240k 4.6a
0.45 jga 21.6a 49Q 5.2a
Group B
0.015 23O 5.loa 260 75&
0.06 280 19.? sioa 16U
0.20 450b 362b 940b 21b
10,000 -
5,000
2,000
1,000
500
200
100
50
20
-t
—.
S
a-z
'C
E
C,,
CC,
a-Values are means (N = 4).
a P < 0.05 versus vehicle
b p C 0.01 versus vehicle
against human ANP (99-126) [121. This antibody shows 100%
cross-reactivity with human ANP (102-126). The normal value
in 40 supine healthy volunteers is 17.9 8.1 pmollliter (mean
When we assume the red-cell volume to be constant during
infusion of ANP, the change in plasma volume (PV) at time t
after the start of the infusion can be calculated from the changes
in hematocrit (Hct) using the following formula:
— I
0 15 30 45 60 75 90
Time, minutes
FIg. 1. Plasma ANP levels before, during and after infusion of human
ANP (102-126) or vehicle in patients with nephrotic syndrome. Doses
are given in j.tglkg/min.
When the total amount of albumin within the vascular compart-
ment remains unaltered, the change in plasma volume at time t
can also be calculated from the changes in serum albumin (AIb)
concentration:
Data are presented as means SEM. The effects of ANP on
the renal excretion of water and solutes, during the 60-minute
infusion period and 60 minutes thereafter, were assessed by
multiple regression analysis, in which ANP was compared to
vehicle. All other data were analyzed by means of one way
analysis of variance. When a significant difference was demon-
strated, the levels at the end of the 60 minute infusion and 120
minutes thereafter were compared with baseline by means of
the Student-Neuman-Keuls test.
The infusions were carried out without complications and
data collection was complete. Results are summarized in Tables
2, 3, and 4. Three subjects experienced a feeling of lightheaded-
ness when standing to urinate, in each case during the last 20
minutes of infusion at the time of the third infusion (0.06 or 0. 10
tg/kgImin).
Basal plasma ANP concentration was normal, 19.2 3.6
pmol/liter. During infusion of human ANP (102-126) plasma
levels of ANP increased at all doses (Fig. 1). Peak levels of
EE
>
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gIkgImin, and it rose after 0.45 ixgIkg/min of ANP. Plasma
noradrenaline rose during infusion of 0.10, and 0.20 and 0.45
gIkgImin of ANP (Table 2).
Discussion
Basal ANP levels were normal in our nephrotic subjects. This
has also been observed by others [13]. During infusion of ANP
at a rate of 0.015 or 0.03 jxglkg/min, plasma ANP rose to values
within the pathophysiological range. At higher doses of ANP
the plasma levels reached pharmacological rather than physio-
logical values.
Infusion of ANP induced natriuresis and diuresis and lowered
blood pressure in our patients. These effects have also been
observed in other disease states as well as in healthy subjects
[1]. The published results in normal subjects cannot be readily
compared to our study because of differences in sodium intake
and baseline urine flow [4, 14]. With these restrictions taken
into account, the increase in sodium and water excretion in our
nephrotic subjects appears to be at least equal to that in normal
subjects. It is perhaps surprising that the effect of ANP on
sodium and water excretion in nephrotics is similar to that in
normal subjects, since the nephrotic syndrome is often associ-
ated with sodium and water retention [15], and the response to
ANP is usually blunted in patients with heart failure or liver
cirrhosis and edema. An attenuation of the natriuretic effect of
ANP has also been reported in nephrotic syndrome in rats [16]
as well as in humans [17]. Our patients were not edematous
when on normal sodium diet. We therefore doubt whether the
results of this study can be extrapolated to patients with
nephrotic syndrome and edema. The effects of ANP appeared
to be blunted in group A as compared to group B. This could be
the result, at least in part, of a somewhat lower daily sodium
intake in group A (126 vs. 155 mmol/24 hr, Table 1), as this
attenuates the renal responsiveness to ANP [14].
Infusion of ANP is known to alter renal hemodynamics. In
normal subjects glomerular filtration rate either increases or is
not altered by ANP, and effective renal plasma flow is lowered
[4, 14]. A consistent finding in previous studies is an increase in
glomerular filtration fraction, calculated as the quotient of
glomerular filtration rate and effective renal plasma flow. In our
patients glomerular filtration rate did not change, effective renal
plasma flow decreased and filtration fraction rose during infu-
sion of ANP. As the renal extraction of hippuran was not
measured, an effect of ANP on proximal tubular excretion of
hippuran cannot be excluded.
A striking observation in the present study is the effect of
ANP on urinary albumin and immunoglobulin G excretion. A
proteinuric effect of a high dose of ANP has been reported in
normal rats [18], but to our knowledge a detailed study on the
proteinuric effect of ANP in patients with nephrotic syndrome
has not been published. In our study of such patients the
increments in albumin excretion after ANP were proportional
to the increments in fractional excretion. Increased fractional
excretion of proteins may be the result of increased transglo-
merular diffusion, increased convection or both [19]. The diffu-
sion component of transglomerular macromolecular transport
will increase when the systemic plasma protein concentration is
increased, when the ultrafiltration coefficient (Kf) is increased
or when the protein concentration in the glomerular capillary
bed is increased by an increased filtration fraction. Convection
will change when the polarity of the basement membrane or the
transcapillary pressure gradient is altered. A change in the
pressure gradient will cause parallel effects on transglomerular
protein filtration and glomerular filtration rate, so that fractional
protein excretion is unaltered [20].
Some of these factors may be operative during infusion of
ANP. First, in our patients the systemic serum concentration of
albumin rose after ANP. Second, an increase in Kf has been
Infusion
1000r l000r
Group A
8001- 8001--
600 F-
Infusion Group B
600 1--
0.45
.0.10
0.03
0.20
400 1--
0.06
200 I-
I I tj
20 40 60 80 100 120 140 160 180
400
200
0 L 1.
—20 0
Time, minutes
Fig. 2. Effect of human ANP (102-126) or vehicle on urinary excretion of sodium in patients with nephrotic syndrome (groups A and B). Doses
are given in tg/kg/min.
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________________________________________________
I I I
0 20 40 60 80 100 120 140 160 180
Time, minutes
Fig. 3. Effect of human AN? (102-126) or vehicle an urinary excretion of albumin and IgG in patients with nephroric syndrome (groups A and B).
Doses are given in g/kg/min.
observed in isolated perfused glomeruli of the dog when ANP
was added to the perfusate [21]. ANP antagonizes angiotensin
Il-induced contraction of the mesangial cells [221, and this will
increase the glomerular capillary surface area and thereby Kf.
Finally, ANP causes an increase in filtration fraction, probably
by reducing afferent arteriolar resistance and by producing an
increase in efferent arteriolar tone [23].
The effect of ANP on protein excretion resembles that of
angiotensin II. Infusion of angiotensin II in the anaesthetized
rat causes an increase in urinary protein excretion through an
increased filtration fraction [241.
The transglomerular transport of albumin is restricted to a
greater extent than would be predicted from its molecular size
[201. The glomerulus possesses a charge-selective barrier to
macromolecular filtration [193, thereby impairing the transglo-
merular transport of albumin, which is negatively charged at
physiological pH. The main barrier to filtration of negatively
charged macromolecules is localized in the glomerular base-
ment membrane at its endothelial side [20]. Although ANP
receptors have been demonstrated on endothelial cells 125],
there is at present no evidence that the polarity of the glomer-
ular basement membrane can be altered by ANP. Moreover,
such changes, if they occur, do not explain why the effect of
ANP on albumin excretion is associated with a parallel effect on
the excretion of immunoglobulin G, which is neutral at physi-
ological pH.
infusion Group B
0.45
0.20
0.06
0.015
0.03
10
I I I
20 0 20 40 60 80 100 120 140 160 180
0.5 r
0-i I I I I I I
—20 0 20 40 60 80 100 120 140 160 180
0.5 r
0.3 I—
0.2
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Fig. 4. Relationship of the decrease in plasma volume, as calculated
from changes in hematocrit, with the decrease in plasma volume, as
calculated from changes in serum albumin, after 60 mm of human ANP
(102-126), in patients with nephrotic syndrome.
At high doses, ANP caused hemoconcentration in our pa-
tients, as indicated by the increase in hematocrit and serum
albumin concentration. An increase in hematocrit was already
observed in the first experiments of de Bold eta! [261, in which
atrial extracts of rats were injected into intact rats. ANP may
cause a shift of plasma fluid from the intravascular to the
extravascular compartment [1]. In our study the reduction of
plasma volume, as calculated from the changes in serum
albumin concentration, was smaller than the reduction of
plasma volume calculated from the changes in hematocnt (Fig.
4), which suggests that the total amount of albumin within the
vascular compartment is reduced by ANP. Assuming a normal
plasma volume in non-edematous nephrotics, as has been
reported [271, the decrease in plasma volume can be estimated
from the increase in hematocrit. From this and from the change
in serum albumin concentration the loss of albumin from the
intravascular compartment can be calculated. For instance,
after 60 minutes of ANP at the highest dose in groups A and B,
the loss of intravascular albumin was calculated to be 3280 and
8250 g, respectively, assuming an initial plasma volume of 2500
ml. This decrease in intravascular albumin was much greater
than the increase in urinary excretion, which was 490 and 940
mg, respectively. If we assume the maximal tubular capacity of
albumin reabsorption in 60 minutes to be 130 to 170 mg [6], the
total amount of filtered albumin can be estimated to be 660 and
1110 mg, respectively. Thus, the estimated loss of albumin from
the intravascular compartment cannot be accounted for by
increased glomerular filtration of this protein. It has been
reported that in the nephrectomized rat the capillary absorption
of extravascular fluid after intravenous administration of hy-
peroncotic albumin was less in animals receiving ANP than in
those receiving vehicle [28]. The decreased capillary absorption
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Fig. S. Relationship of the plasma level of ANP with the changes in
urinary excretion of sodium (•, U) and albumin (0, 0) inpatients with
nephrotic syndrome following infusion of human ANP (102-106).
of extravascular fluid in these animals could be the result of
increased capillary filtration of intravascular protein. Our re-
suits suggest a similar phenomenon in nephrotic subjects.
The effect of high doses of ANP on blood pressure lasted
longer (120 mm) than the effect on urinary sodium and protein
excretion, and this long duration contrasts with the short
plasma half-life of ANP (180 sec) [11. The ANP-induced plasma
volume contraction may have contributed to this long lasting
effect on blood pressure. The fall in blood pressure was
associated with an increase in plasma noradrenaline and heart
rate, at least at the three highest doses of ANP, probably due to
baroreflex-mediated increase of sympathetic tone. Plasma renin
was suppressed at low doses of ANP but it was stimulated at
higher doses. The suppression of renin might have been caused
by a direct effect of ANP on the juxtaglomerular cells [29],
whereas the rise of renin might have been caused by sympa-
thetic stimulation in response to plasma volume contraction and
the fall in blood pressure.
The lowest dose of ANP caused a rise of plasma ANP to
levels slightly above the physiological range and this was
already sufficient to induce natriuresis and diuresis, and to
increase proteinuria in our patients (Fig. 5). The effective
threshold dose is therefore likely to be close to the physiological
secretion of ANP. As hemoconcentration occurred at the
highest doses only, this effect of ANP may be pharmacological
rather than physiological [30].
In conclusion, ANP appears to increase the transcapillary
filtration of intravascular protein in the glornerulus and else-
where in the body. In non-edematous patients with nephrotic
syndrome the proteinuretic and natriuretic effects were already
seen at low doses. Endogenous ANP may therefore have
similar effects in these patients.
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